[Secondary osteoporosis UPDATE. Drugs under development for metabolic bone disease].
For the treatment of osteoporosis, anti-resorptive agents including bisphosphonates and raloxifene are widely used. As new anti-resorptive drugs, anti-RANKL antibody and cathepsin K inhibitor are under development. Among bone anabolic agents, daily subcutaneous injection of teriparatide will soon become available in Japan. In addition, new anabolic agents such as calcilitycs and anti-sclerostin antibody are under clinical or preclinical development for the treatment of osteoporosis.
Endo
Itsuro
I
Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Medical Sciences.
Matsumoto
Toshio
T
D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D002403:Cathepsins / Q000037:antagonists & inhibitors; D004164:Diphosphonates; D055808:Drug Discovery; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D020849:Raloxifene Hydrochloride; D020845:Selective Estrogen Receptor Modulators; D019379:Teriparatide
D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D020845:Selective Estrogen Receptor Modulators; D019379:Teriparatide; D020849:Raloxifene Hydrochloride; D002403:Cathepsins